Bioanalysis of Cannabinoids
Precise Cannabinoid PK. From Early Pre-Clinical to GCP.
Bespoke LC-MS/MS assays for CBD, THC, and their metabolites across multiple species and matrices, with sensitivity down to 0.125 ng/mL.
Cannabinoids are a class of compounds that have been utilized extensively due to the breadth of their therapeutic potential.
Resolian’s LC-MS team provides significant expertise in the development and validation of bespoke LC-MS assays to measure the pharmacokinetics (PK) of cannabinoids from early-stage pre-clinical dog, rat and mouse studies up to regulated GCP studies.
The team’s experience of the CBD and THC molecules and their metabolites covers numerous matrices – some assays include up to 8 analytes in a single analysis with sensitivity down to 0.125 ng/mL.
In addition to these, Resolian has developed and validated a variety of proprietary methods across a broad range of species and matrices.
Reach out to us directly to learn more about Resolian’s Bioanalysis of Cannabinoids services.
Ready to develop a validated cannabinoid bioanalysis method for your study?
Partner with an LC-MS team that brings specialist cannabinoid expertise, multi-analyte capability,
and a proven track record from early-stage rodent studies through regulated GCP clinical trials.
Our Bioanalytics Resources
Case Studies
Measuring What Matters: High-Precision Plasma Protein Binding Assessment for Highly Bound Compounds Under ICH M12
Case Studies
Solving Carboplatin: A Novel LC-MS/MS Assay for Intact Drug Quantitation in Human Plasma
Blog, Publications
When AI Meets Experimental Biology: Supporting Breakthrough Peptide Research
Case Studies
Developing and Validating a Simple, Rapid LC-MS/MS Method for Semaglutide in Human Plasma
